Bayer HealthCare Diagnostics and Oxford Genome Sciences Partner in Proteomics-based Evaluation of New Biomarkers

18-Mar-2005

Oxford Genome Sciences (UK) Ltd (OGeS) announced that it has entered into a collaboration with Bayer HealthCare AG Diagnostics Division, a member of the Bayer Group. OGeS will apply its highly-innovative proteomics platform, in conjunction with its unique Oxford Genome anatomy Project (OGAP(TM)), the world's largest proteomics database, to evaluate novel candidate biomarkers that may have important applications in clinical care for the diagnosis and prognostic assessment of breast cancer. Under the agreement, Bayer Diagnostics has committed programme funding to OGeS and agreed to performance-related payments upon achieving certain milestones.

The biomarkers for breast cancer were identified by Bayer HealthCare previously using gene arrays. Through this collaboration, OGeS will apply its proteomics technologies to the discovery and development of novel therapeutic and diagnostic products that will improve human health by enabling better-targeted and more effective treatment regimes for breast cancer.

OGeS will leverage OGAP(TM) - the world's largest proteomics database to date: over one million peptide sequences from approximately 50 different tissues involved in close to 60 different diseases have been mapped onto 15,000 human genes integrated with the entire genome and over five million single nucleotide polymorphisms (SNPs). OGAP offers a data integration framework to explain the size and diversity of the human proteome at the tissue, disease and protein isoform levels.

https://www.bionity.com/en/news/44445/bayer-healthcare-diagnostics-and-oxford-genome-sciences-partner-in-proteomics-based-evaluation-of-new-biomarkers.html